Latest News

Avantium NV bags money for demo plant

© Avantium NV


by tg

Green chemistry company Avantium NV has secured a €7.5m funding from the National Programme Groningen to support the construction of a 5 kilotonnes FDCA plant.

The new grant is part of a €30m financing mix that Avantium and the Groningen consortium announced this January.

FDCA is the key building block for PEF (polyethylene furanoate), a plant-based, fully recyclable plastic material that outperforms today’s standard PET with regards to environmental footprint and performance. The FDCA flagship plant to be built in Delfzijl is planned to start up in 2023. This will provide around 60 jobs in the region. 

Avantium and the Groningen consortium already entered into an agreement earlier this year relating to the conditional financing mix of €30m for the construction of the FDCA plant.  The Groningen consortium comprises of the Province of Groningen, Groningen Seaports and regional investment funds NOM (Investment and Development Agency for the Northern Netherlands), FondsNieuweDoen, Investeringsfonds Groningen and Groeifonds.

Evotec expanding at Milton Park campus

According to Evotec, adding a new building by the end of the year, will bring together all the key functions for small molecule discovery and up to...

How microplastic particles get into the body

Microplastic particles exposed to freshwater or saltwater environments for several weeks are about ten times more likely than pristine particles to...

Topas raises €22m in Series B financining

Topas Therapeutics GmbH has closed a €22m (~$26mn) Series B financing round co-led by Vesalius BioCapital III and BioMedPartners with participation...

LSP reports first closing of dementia fund

The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...

Vifor Pharma in US$100m licence deal with Cara Therapeutics

Under the licence deal with the US company Cara Therapeutics Inc., Swiss Vifor Pharma has acquired the US commercialisation rights for intravenous...

Atriva Therapeutics gets €24m from EIB

According to Atriva Therapeutics, the proceeds allow the company to start Phase II testing of its oral MEK inhibitor ATR-002. In preclinical trails,...

German researchers find reason for remdesivir's inefficiency

“We have come to a simple conclusion,” said Max Planck Director Patrick Cramer at the MPI for Biophysical Chemistry. “Remdesivir does interfere with...